1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-sulfonamide | 1803602-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-sulfonamide
• 英文别名: 1,3-dimethylpyrazolo[3,4-b]pyridine-5-sulfonamide
• CAS: 1803602-09-6
• 化学式: C₈H₁₀N₄O₂S
• 分子量: 226.26
• InChiKey: BAQGDGUVNHCROC-UHFFFAOYSA-N

物化性质

• 沸点：
  468.3±55.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  99.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
  申请人：Inflazome Limited

  公开号：US11370776B2

  公开（公告）日：2022-06-28

  The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

  本发明涉及式（I）化合物： 其中 Q 是 O 或 S，R1 是在 6 元环结构中含有至少一个氮原子的 6 元杂芳基，其中 R1 可任选被取代，R2 是在α 位被取代的环状基团，其中 R2 可任选被进一步取代。本发明进一步涉及此类化合物的盐、溶液剂和原药，涉及包含此类化合物的药物组合物，涉及此类化合物在治疗和预防医学紊乱和疾病中的用途，特别是通过抑制 NLRP3。
• SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS
  申请人：Inflazome Limited

  公开号：US20200270227A1

  公开（公告）日：2020-08-27

  The present invention relates to compounds of formula (I): wherein Q is O or S, R 1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R 1 may optionally be substituted, and R 2 is a cyclic group substituted at the α-position, wherein R 2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
• NOVEL COMPOUNDS
  申请人：Inflazome Limited

  公开号：US20210002274A1

  公开（公告）日：2021-01-07

  The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R 1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; R 2 is a cyclic group substituted at the a and a′ positions, wherein the substituent at the α-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted; R 3 and R 4 are each independently hydrogen, halogen, —OH, —NH 2 , —CN, —R 5 , —OR 5 , —NHR 5 or —N(R 5 ) 2 ; or R 3 and R 4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R 5 is independently optionally substituted C 1 -C 4 alkyl. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
• [EN] SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS<br/>[FR] SULFONYLURÉES ET SULFONYLTHIOURÉES EN TANT QU'INHIBITEURS DE NLRP3
  申请人：INFLAZOME LTD

  公开号：WO2019008029A1

  公开（公告）日：2019-01-10

  The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.